SCHEMBL25414906

SCHEMBL25414906

N#Cc1ccc(Cl)cc1C(=O)N(CCNC(=O)O)c1ccccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 2/20 0.38
SIGMAR1 Q99720 2/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
ALDH1A1 P00352 5/20 0.37
LMNA P02545 4/20 0.37
GAA P10253 2/20 0.37
KDM4E B2RXH2 1/20 0.37
TSHR P16473 1/20 0.35
GPBAR1 Q8TDU6 3/20 0.34
HTT P42858 2/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP2D6 P10635 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
NOS2 P35228 1/20 0.34
MAPT P10636 1/20 0.33
S1PR3 Q99500 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25411640 0.88 TSHR (0.44) TMEM97SIGMAR1MEN1KMT2AMRGPRX4
SCHEMBL26313781 0.85 IDO1 (0.40) TMEM97SIGMAR1MEN1KMT2AALDH1A1
SCHEMBL30597297 0.85 IDO1 (0.40) TMEM97SIGMAR1MEN1KMT2AALDH1A1
SCHEMBL26313650 0.84 GPBAR1 (0.43) MEN1KMT2AMRGPRX4ALDH1A1LMNA
SCHEMBL25411335 0.84 CYP3A4 (0.47) MEN1KMT2AMRGPRX4ALDH1A1LMNA
SCHEMBL25412959 0.84 TMEM97 (0.40) TMEM97SIGMAR1MEN1KMT2ALMNA
SCHEMBL25414911 0.80 MRGPRX4 (0.37) MEN1KMT2AMRGPRX4ALDH1A1LMNA
SCHEMBL25409199 0.80 NOS2 (0.40) TMEM97SIGMAR1MEN1KMT2AALDH1A1
SCHEMBL25412807 0.75 TSHR (0.42) MRGPRX4ALDH1A1LMNAGAAKDM4E
SCHEMBL25414739 0.75 TSHR (0.43) TMEM97SIGMAR1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286913-A1 INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF Gacter Inc. (US) 2023-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286913-A1 INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF NOS1, NOS3, NOS2 TMEM97 3277/4885SIGMAR1 641/4885MEN1 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.